- Whitworth PW et al. ASBS; Abstract: Interim Analysis of the DCISionRT PREDICT Study: Clinical Utility of a Biologic Signature Predictive of Radiation Therapy Benefit in Patients with DCIS
- Warnberg, F et al. A Validation of DCIS Biological Risk Profile in a Randomised Study for Radiation Therapy with 20 Year Follow-up (SweDCIS), SABCS 2017; Abstract: 851741
- Bremer, TM et al. MBCC 2017 Poster: Utility of the DCIS Biological Risk Profile for Predicting Recurrence Risk Compared to Standard Clinicopathologic Factors
- Bremer, TM et al. A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy (RT) Benefit and Assess Recurrence Risk. Clinical Cancer Research 2018; published online 12/01/2018.
This test was developed and its performance characteristics determined by PreludeDx. It has not been cleared or approved by the FDA. This test is used for clinical purposes and should not be regarded as investigational or for research. The laboratory is certified under CLIA-88 as qualified to perform high complexity clinical testing.